CARDIOVASCULAR
hamburger

PORTFOLIO OVERVIEW

  • Providing innovative implantable devices and leads designed to improve outcomes and reduce heart failure hospitalizations
  • Offering multiple industry-leading technologies for comprehensive arrhythmia management
  • Reducing patient and hospital costs through wireless telemetry and improved patient monitoring
TherArrhyMgmt_AssurityFamily-Leads
THE EVOLUTION OF CARDIAC ARRHYTHMIA TREATMENT

Cardiac arrhythmias place a heavy burden on health care systems worldwide. Atrial tachycardia (AT) and atrial fibrillation (AF) result in significant cost to health care systems.1 Patients with AT and AF are at an increased risk for stroke, dementia, heart failure and death,2 and ventricular tachycardia (VT) and ventricular fibrillation (VF) are fatal without treatment. Ventricular tachycardia and VF remain the most significant causes of sudden cardiac death in America,3 at an estimated rate of 300,000 deaths per year.4

At Abbott, we offer a portfolio of products with the versatility to diagnose and manage an array of cardiac arrhythmias. Our comprehensive arrhythmia management, including wireless telemetry pacemakers, leads with the first insulation created specifically for cardiac use and ICDs with diagnostic algorithms for continuous monitoring, empowers care across the entire patient care continuum. Our portfolio of products help you provide cost-effective and complete patient management.

PRODUCTS IN THIS PORTFOLIO
THE WORLD’S SMALLEST, LONGEST-LASTING WIRELESS MRI PACEMAKER*

The Assurity MRI™ pacemaker and Tendril MRI™ lead are designed specifically to allow full-body, 1.5T MRI scans.** Wireless remote monitoring and other safety features are designed for fewer complications and greater patient comfort.

See the many advantages and premium features of the Assurity MRI™ pacemaker.

 

DEDICATED TO EXCEPTIONAL CLINICAL LEADERSHIP

At Abbott, responsible and visionary clinical leadership helps us reduce the cost of health care, lessening the impact of epidemic disease on patients and their families. In the area of cardiac arrhythmia management, we dedicate our clinical leadership efforts to:

  • Designing and facilitating comprehensive, robust and globally relevant analysis and clinical studies
  • Reducing mortality rates and decreasing hospitalizations while improving quality of life
  • Improving product performance and eliminating inappropriate shocks

Our clinical successes allow us to offer an unparalleled portfolio of cardiac arrhythmia management products.

LOWERING THE COST OF TREATMENT 

ICDs and pacemakers with remote monitoring have shown impressive cost reduction opportunities. Studies of the use of remote monitoring in the U.S. show:

 

  • 36% decrease in cardiac or device-related emergency department or hospital visits5
  • 17% reduction in spending (approximately $10,640 per ICD/CRT-D patient) over 3 years6
  • 9% reduction in spending (approximately $4,356 per pacemaker patient) over three years6
  • 18% reduction in length of hospital stay (an estimated savings of $1,793/stay, per patient)7

 

At Abbott, we focus our attention on providing cost-effective disease-management solutions for cardiac arrhythmias, heart failure and hypertension, cardiovascular disease and structural heart disease. Our goal is to enhance patient access to appropriate and affordable medical care.

chart showing that patients with remote monitoring cost less to manage across the health care system
CUSTOMER
SERVICE

Our customer service experts can help with your
product orders or questions.

 

a natural wonder of sandstone caves

OUR PRODUCTS

See our featured innovations and technologies, full product catalog and approach to disease state management.

REFERENCES

*Among pacemakers < 15cc in total volume; as of February 1, 2017. St. Jude Medical. (2016). St. Jude Medical Research Report: Competitive Product Review: Wireless Pacemakers. No. 60082151.

**See MRI Ready Systems Manual for information regarding specific models of MRI Ready leads and associated parameters.

1. Shah, A., Merchant, F. M., Delurgio, D. B., (2016). Atrial fibrillation and risk of dementia/cognitive decline. Journal of Atrial Fibrillation. 8(5):1353. http://dx.doi.org/10.4022/jafib.1353

2. Kelly, P., (2014). Preventing the rise of atrial fibrillation-related stroke in populations: A call to action. Circulation.130: 1221-22. http://dx.doi.org/10.1161/CIRCULATIONAHA.114.012738

3. Tang, P. T., Shenasa, M., Boyle, N. G., (2017). Ventricular arrhythmias and sudden cardiac death. Cardiac Electrophysiology Clinic. 9(4):693-708. http://dx.doi.org/10.1016/j.ccep.2017.08.004

4. Ellenbogen, K. A., Wan, C., Shavelle, D. M., (2017). Outcome of patients with in-hospital ventricular tachycardia and ventricular fibrillation arrest while using a wearable cardioverter defibrillator. American Journal of Cardiology. 121(2):205-9. http://dx.doi.org/10.1016/j.amjcard.2017.10.007

5. Perego. G., Landolina, M., Lunati, M., Curnis. A., Guenzati, G., Balla, E., … , Marzegalli, M. (2012, May). REMOTE MONITORING REDUCES HEALTHCARE UTILIZATION AND IMPROVES QUALITY OF CARE IN HEART FAILURE PATIENTS WITH IMPLANTABLE DEFIBRILLATOR: THE EVOLVO STUDY. Presented at the meeting of the Heart Rhythm Society, Boston, MA.

6. Sutton, B., Zigler, J., Gopinathannair, R., Deam, G., & Graver, R. (2013, May). Improved health outcomes and cost-savings with remote monitoring of cardiac implantable electronic devices. Presented at the meeting of the Heart Rhythm Society, Denver, CO. Retrospective claims analysis of Medicare 5% sample Limited Data Set Standard Analytical Files claims and enrollment data across all manufacturers.

7. Crossley, G. H., Boyle, A., Vitense, H., Chang, Y., Mead, R. H., & CONNECT Investigators. (2011). The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: The value of wireless remote monitoring with automatic clinician alerts. Journal of the American College of Cardiology, 57(10), 1181-1189.http://dx.doi.org/10.1016/j.jacc.2010.12.012

SJM-CV WEB-0718-0011

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?